| Literature DB >> 36016364 |
Abou Abdallah Malick Diouara1, Seynabou Lo2,3, Cheikh Momar Nguer1, Assane Senghor1, Halimatou Diop Ndiaye4, Noël Magloire Manga5,6, Fodé Danfakha7, Sidy Diallo8, Marie Edouard Faye Dieme9, Ousmane Thiam3, Babacar Biaye10, Ndèye Marie Pascaline Manga4, Fatou Thiam1, Habibou Sarr5,6, Gora Lo11, Momar Ndour2, Sébastien Paterne Manga6, Nouhou Diaby12, Modou Dieng13, Idy Diop14, Yakhya Dieye1, Coumba Toure Kane11,15, Martine Peeters16, Ahidjo Ayouba16.
Abstract
In West Africa, research on the hepatitis E virus (HEV) is barely covered, despite the recorded outbreaks. The low level of access to safe water and adequate sanitation is still one of the main factors of HEV spread in developing countries. HEV infection induces acute or sub-clinical liver diseases with a mortality rate ranging from 0.5 to 4%. The mortality rate is more alarming (15 to 25%) among pregnant women, especially in the last trimester of pregnancy. Herein, we conducted a multicentric socio-demographic and seroepidemiological survey of HEV in Senegal among pregnant women. A consecutive and non-redundant recruitment of participants was carried out over the period of 5 months, from March to July 2021. A total of 1227 consenting participants attending antenatal clinics responded to a standard questionnaire. Plasma samples were collected and tested for anti-HEV IgM and IgG by using the WANTAI HEV-IgM and IgG ELISA assay. The overall HEV seroprevalence was 7.8% (n = 96), with 0.5% (n = 6) and 7.4% (n = 91) for HEV IgM and HEV IgG, respectively. One of the participant samples was IgM/IgG-positive, while four were declared indeterminate to anti-HEV IgM as per the manufacturer's instructions. From one locality to another, the seroprevalence of HEV antibodies varied from 0 to 1% for HEV IgM and from 1.5 to 10.5% for HEV IgG. The data also showed that seroprevalence varied significantly by marital status (p < 0.0001), by the regularity of income (p = 0.0043), and by access to sanitation services (p = 0.0006). These data could serve as a basis to setup national prevention strategies focused on socio-cultural, environmental, and behavioral aspects for a better management of HEV infection in Senegal.Entities:
Keywords: Senegal; associated risk factors; environment; hepatitis E; pregnant women; prevention
Mesh:
Substances:
Year: 2022 PMID: 36016364 PMCID: PMC9416362 DOI: 10.3390/v14081742
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Figure 1Map of Senegal, with indication of the geographical sites of the study.
Socio-demographic characteristics of pregnant women and HEV markers.
| Variable | Study Sites | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Saint-Louis | Dakar | Kédougou | Ziguinchor | All Sites | ||||||
| Frequency (%) | Median | Frequency (%) | Median | Frequency (%) | Median | Frequency (%) | Median | Frequency (%) | Median | |
|
| ||||||||||
| 18–23 | 112 (28) | 20 | 49 (29.5) | 21 | 256 (64.5) | 19 | 111 (42) | 20 | 528 (43) | 20 |
| 24–29 | 136 (34) | 26 | 44 (26.5) | 27 | 90 (22.7) | 26 | 87 (33) | 26 | 357 (29.1) | 26 |
| 30–35 | 101 (25.3) | 32 | 48 (28.9) | 32.5 | 29 (7.3) | 30 | 45 (17) | 32 | 223 (18.2) | 32 |
| 36 and above | 51 (12.8) | 36 | 25 (15.1) | 37 | 22 (5.5) | 38 | 21 (8) | 39 | 119 (9.7) | 38 |
|
| ||||||||||
| None | 62 (15.5) | . | 25 (15.1) | . | 233 (58.7) | . | 69 (26.1) | . | 389 (31.7) | . |
| Primary | 170 (42.5) | . | 46 (27.7) | . | 82 (20.7) | . | 77 (29.2) | . | 375 (30.6) | . |
| Secondary | 122 (30.5) | . | 52 (31.3) | . | 75 (18.9) | . | 104 (39.4) | . | 353 (28.8) | . |
| Higher | 46 (11.5) | . | 43 (25.9) | . | 7 (1.8) | . | 14 (5.3) | . | 110 (9) | . |
|
| ||||||||||
| unspecified | 11 (2.8) | . | 0 (0) | . | 16 (4.0) | . | 4 (1.5) | . | 31 (2.5) | . |
| Single | 8 (2) | . | 6 (3.6) | . | 12 (3) | . | 39 (14.8) | . | 65 (5.2) | . |
| Married | 381 (95.3) | . | 160 (96.4) | . | 369 (93) | . | 220 (83.3) | . | 1130 (92) | . |
| Divorced or widowed | 0 (0) | . | 0 (0) | . | 0 (0) | . | 1 (0.4) | . | 1 (0.08) | . |
|
| ||||||||||
| unspecified | 6 (1.5) | . | 1 (0.6) | . | 36 (9.1) | . | 4 (1.5) | . | 47 (3.8) | . |
| Yes | 47 (11.8) | . | 76 (45.8) | . | 63 (15.9) | . | 43 (16.3) | . | 229 (18.7) | . |
| No | 347 (86.8) | . | 89 (53.6) | . | 298 (75.1) | . | 217 (82.2) | . | 951 (77.5) | . |
|
| ||||||||||
| unspecified | 2 (0.5) | . | 0 (0) | . | 24 (6) | . | 5 (1.9) | . | 31 (2.5) | . |
| Occasionally | 0 (0) | . | 0 (0) | . | 0 (0) | . | 10 (3.8) | . | 10 (0.8) | . |
| Yes | 387 (96.8) | . | 166 (100) | . | 311 (78.3) | . | 98 (37.1) | . | 962 (78.4) | . |
| No | 11 (2.8) | . | 0 (0) | . | 62 (15.6) | . | 151 (57.2) | . | 224 (18.3) | . |
|
| ||||||||||
| unspecified | 1 (0.3) | . | 0 (0) | . | 12 (3) | . | 5 (1.9) | . | 18 (1.5) | . |
| Occasionally | 0 (0) | . | 0 (0) | . | 0 (0) | . | 5 (1.9) | . | 5 (0.4) | . |
| Yes | 388 (97) | . | 166 (100) | . | 363 (91.4) | . | 141 (53.4) | . | 1058 (86.2) | . |
| No | 11 (2.8) | . | 0 (0) | . | 22 (5.5) | . | 113 (42.8) | . | 146 (11.9) | . |
|
| ||||||||||
| unspecified | 1 (0.3) | . | 0 (0) | . | 28 (7.1) | . | 3 (1.1) | . | 32 (2.6) | . |
| Occasionally | 59 (14.8) | . | 0 (0) | . | 0 (0) | . | 1 (0.4) | . | 60 (4.9) | . |
| Yes | 285 (71.3) | . | 166 (100) | . | 348 (87.7) | . | 182 (68.9) | . | 981 (79.9) | . |
| 55 (13.8) | . | 0 | . | 21 (5.3) | . | 78 (29.5) | . | 154 (12.5) | . | |
|
| ||||||||||
| unspecified | 0 (0) | . | 0 (0) | . | 16 (4) | . | 4 (1.5) | . | 20 (1.6) | . |
| Occasionally | 0 (0) | . | 0 (0) | . | 0 (0) | . | 6 (2.3) | . | 6 (0.5) | . |
| Yes | 392 (98) | . | 166 (100) | . | 350 (88.2) | . | 206 (78) | . | 1114 (90.8) | . |
| No | 8 (2) | . | 0 (0) | . | 31 (7.8) | . | 48 (18.2) | . | 87 (7.1) | . |
|
| ||||||||||
| HEV IgM Positive | 2 (0.5) | . | 0 (0) | . | 4 (1) | . | 0 (0) | . | 6 (0.5) | . |
| HEV IgG Positive | 42 (10.5) | . | 7 (4.2) | . | 38 (9.6) | . | 4 (1.5) | . | 91 (7.4) | . |
Variability of HEV IgM and IgG serological markers according to age groups and localities.
| IgM HEV | IgG HEV | |||
|---|---|---|---|---|
| [Age Groups] (%) | ||||
| [ | 1 (0.18) | 0.0372 | 28 (5.30) | 0.0048 |
| [ | 2 (0.56) | 26 (7.28) | ||
| [ | 2 (0.89) | 19 (8.52) | ||
| ≥36 years, | 1 (0.84) | 18 (15.12) | ||
|
| 6 (0.48) | 91 (7.41) | ||
|
| ||||
| Saint-Louis ( | 2 (0.50) | 0.3293 | 42 (10.50) | 0.0133 |
| Dakar ( | 0 (0.00) | 7 (4.21) | ||
| Ziguinchor ( | 0 (0.00) | 4 (1.51) | ||
| Kédougou ( | 4 (1.00) | 38 (9.57) | ||
|
| 6 (0.48) | 91 (7.41) | ||
Prevalance of HEV IgM and IgG markers and potential associated factors.
| IgM HEV | IgG HEV | ||||||
|---|---|---|---|---|---|---|---|
| Educational Level | Frequency (%) |
| Prevalence |
| Prevalence | ||
| None | 389 (31.7) | 4 | 1.03 | 0.4655 | 32 | 8.23 | 0.4017 |
| Primary | 375 (30.6) | 1 | 0.27 | 30 | 8 | ||
| Secondary | 353 (28.8) | 1 | 0.28 | 25 | 7.08 | ||
| Higher | 110 (9) | 0 | 0 | 4 | 3.64 | ||
|
| |||||||
| unspecified | 31 (2.5) | 0 | 0 | 0.9999 | 2 | 6.45 | < 0.0001 |
| Single | 65 (5.2) | 0 | 0 | 7 | 10.77 | ||
| Maried | 1130 (92) | 6 | 0.53 | 82 | 7.26 | ||
| Divorced or widowed | 1 (0.08) | 0 | 0 | 0 | 0 | ||
|
| |||||||
| unspecified | 47 (3.8) | 0 | 0 | 1 | 1 | 2.13 | 0.0043 |
| Yes | 229 (18.7) | 1 | 0.44 | 12 | 5.24 | ||
| No | 951 (77.5) | 5 | 0.53 | 78 | 8.2 | ||
|
| |||||||
| unspecified | 31 (2.5) | 1 | 3.23 | 0.1958 | 2 | 6.45 | 0.4001 |
| Occasionally | 10 (0.8) | 0 | 0 | 0 | 0 | ||
| Yes | 962 (78.4) | 4 | 0.42 | 78 | 8.11 | ||
| No | 224 (18.3) | 1 | 0.45 | 11 | 4.91 | ||
|
| |||||||
| unspecified | 18 (1.5) | 0 | 0 | 1 | 2 | 11.11 | 0.0006 |
| Occasionally | 5 (0.4) | 0 | 0 | 0 | 0 | ||
| Yes | 1058 (86.2) | 6 | 0.57 | 87 | 8.22 | ||
| No | 146 (11.9) | 0 | 0 | 2 | 1.37 | ||
|
| |||||||
| unspecified | 32 (2.6) | 0 | 0 | 1 | 2 | 6.25 | 0.5984 |
| Occasionally | 60 (4.9) | 0 | 0 | 6 | 10 | ||
| Yes | 981 (79.9) | 6 | 0.61 | 75 | 7.65 | ||
| No | 154 (12.5) | 0 | 0 | 8 | 5.19 | ||
|
| |||||||
| unspecified | 20 (1.6) | 0 | 0 | 0.4406 | 2 | 10 | 0.1950 |
| Occasionally | 6 (0.5) | 0 | 0 | 0 | 0 | ||
| Yes | 1114 (90.8) | 5 | 0.45 | 87 | 7.81 | ||
| No | 87 (7.1) | 1 | 1.15 | 2 | 2.3 | ||